Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 4/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179216 | 0.80 | HRH3 (0.53) | HRH3 | |
| SCHEMBL4167207 | 0.80 | PPARG (0.40) | KDM4EALDH1A1HRH3L3MBTL1TDP1 | |
| SCHEMBL8236467 | 0.79 | POLB (0.39) | ITGB3ITGA2BPOLBKDM4EALDH1A1 | |
| SCHEMBL4173331 | 0.79 | HRH3 (0.62) | HRH3LTA4HMEN1KMT2A | |
| SCHEMBL4177653 | 0.78 | HRH3 (0.52) | HRH3 | |
| SCHEMBL4166038 | 0.76 | DRD3 (0.53) | HRH3TDP1MEN1KMT2A | |
| SCHEMBL4167552 | 0.72 | CYP3A4 (0.49) | KDM4ETDP1MEN1HTTKMT2A | |
| Hydrochloric Acid SCHEMBL9600346 | 0.69 | POLB (0.40) | ITGB3ITGA2BPOLBKDM4EALDH1A1 | |
| SCHEMBL7902910 | 0.68 | KDM4E (0.38) | ITGB3ITGA2BPOLBKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL9265087 | 0.68 | POLB (0.38) | ITGB3ITGA2BPOLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090017112-A1 | Compounds for Inhibiting Beta-Amyloid Production | ROSKAMP RESEARCH LLC (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1993548-A2 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION | Roskamp Research LLC (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007103683-A2 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION | ROSKAMP RESEARCH LLC (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017112-A1 | Compounds for Inhibiting Beta-Amyloid Production | PSEN1, PSEN2, APP | ITGB3 3404/4885ITGA2B 3123/4885POLB 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.